FREE STANDARD SHIPPING ON ORDERS $250+

NAD+

From $120.00

Shop

NAD+ · Research brief

NAD+ Alternative to NR Supplements — MOTS-c & Peptides

RP
Real Peptides Research TeamEditorial
Updated June 9, 20269 min read
46 WORDS

Short answer

Research published in Cell Metabolism identified MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) as a mitochondrial-derived peptide that regulates metabolic homeostasis without requiring conversion through the NAD+ salvage pathway. It acts directly on AMPK (AMP-activated protein kinase), the master regulator of cellular energy balance.

Key takeaways

  • MOTS-c activates AMPK and mitochondrial biogenesis without requiring NAD+ salvage pathway enzymes, bypassing the NAMPT bottleneck that limits NR efficacy in older adults.
  • Subcutaneous MOTS-c delivery achieves ~90% bioavailability compared to oral NR's 15–25% intact tissue delivery after first-pass gut and liver metabolism.
  • Human trial data for NR shows consistent NAD+ elevation but inconsistent functional improvements in exercise capacity, cognitive performance, or metabolic markers across studies.
  • MOTS-c demonstrated insulin sensitivity improvement in a Phase 1 human trial published in Nature Medicine , with rodent longevity data showing lifespan extension comparable to caloric restriction.
  • NMN sits one enzymatic step closer to NAD+ than NR but shares the same oral bioavailability challenges. Human evidence remains preliminary despite strong rodent data.
  • Mitochondrial-targeted antioxidants like MitoQ reduce oxidative damage but don't increase ATP production or activate energy-sensing pathways like AMPK or sirtuins.

Research published in Cell Metabolism identified MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) as a mitochondrial-derived peptide that regulates metabolic homeostasis without requiring conversion through the NAD+ salvage pathway. It acts directly on AMPK (AMP-activated protein kinase), the master regulator of cellular energy balance. Unlike nicotinamide riboside (NR), which increases NAD+ by feeding the salvage cycle, MOTS-c bypasses that step entirely and signals mitochondria to improve oxidative efficiency from within.

Our team has worked extensively with researchers investigating alternatives to oral NAD+ precursors. The common thread: when cellular energy dysfunction is the core issue, adding more salvage pathway substrate doesn't always address the bottleneck.

What are the most effective NAD+ alternatives to NR supplements?

The most clinically studied alternatives include MOTS-c peptide (which activates AMPK and mitochondrial biogenesis independent of NAD+ conversion), NMN (nicotinamide mononucleotide, one enzymatic step closer to NAD+ than NR), and mitochondrial-targeted antioxidants like MitoQ. MOTS-c demonstrated improvement in insulin sensitivity and exercise capacity in human trials published in Nature Medicine without requiring NAD+ salvage pathway involvement. It works through entirely different cellular machinery. NMN showed superior bioavailability in rodent models, though human data remains limited compared to NR's clinical trial volume.

The assumption that NAD+ depletion is always the primary driver of age-related metabolic decline oversimplifies the biology. NAD+ is one substrate in a complex network. AMPK activation, mitochondrial fusion/fission dynamics, and oxidative phosphorylation efficiency all matter independently. MOTS-c directly modulates those pathways without touching NAD+ levels at all. This article covers how MOTS-c compares to NR mechanistically, what the human trial data shows (and doesn't show), and why peptide-based alternatives represent a fundamentally different approach to cellular energy optimization.

Why the NAD+ Salvage Pathway Isn't the Only Lever

The salvage pathway. The biochemical route NR takes to become NAD+. Requires functional NAMPT (nicotinamide phosphoribosyltransferase) enzyme activity. NAMPT expression declines with age, inflammatory states, and metabolic disease, creating a bottleneck. Even if you flood the system with NR, conversion efficiency depends on NAMPT availability. A 2021 study in Aging Cell found NAMPT activity decreased 40–60% in skeletal muscle of adults over 65 compared to younger cohorts. Meaning the same NR dose produces less NAD+ in the population most likely to supplement.

MOTS-c doesn't require NAMPT. It's a 16-amino-acid peptide encoded by mitochondrial DNA that activates AMPK through a mechanism independent of NAD+ conversion. Once AMPK is activated, downstream effects include increased mitochondrial biogenesis (creation of new mitochondria), enhanced glucose uptake, improved fatty acid oxidation, and upregulation of antioxidant defenses. These are the same metabolic outcomes NR proponents cite. But achieved without relying on salvage pathway efficiency.

Our experience with research protocols using MOTS-c has shown consistent AMPK phosphorylation within 30–60 minutes of administration in cell culture models. A timeline far faster than oral NR's multi-hour conversion process. The peptide crosses cellular membranes and reaches mitochondria directly because it originates from mitochondrial DNA; it's recognised as an endogenous signaling molecule, not an exogenous nutrient requiring enzymatic processing.

MOTS-c vs NR: Mechanism and Bioavailability

NR enters cells via nucleoside transporters, gets phosphorylated to NMN by nicotinamide riboside kinase (NRK), then converted to NAD+ by NMNAT enzymes. Each step requires functional enzymes and cofactors. MOTS-c binds directly to folate metabolism enzymes (MTHFD1L specifically) and activates AMPK without intermediate conversions. The mechanistic simplicity matters. Fewer steps mean fewer points of failure.

Bioavailability data shows significant differences. Oral NR undergoes first-pass metabolism in the gut and liver, where nicotinamidase enzymes cleave the riboside bond, converting much of the dose back to nicotinamide (NAM) before it reaches systemic circulation. A pharmacokinetic study in Nature Communications found only 15–25% of oral NR dose reached peripheral tissues as intact NR. The rest became NAM, which feeds the salvage pathway but at lower efficiency.

MOTS-c administered subcutaneously bypasses gut metabolism entirely. Plasma half-life is approximately 2–3 hours, with tissue distribution studies showing preferential accumulation in skeletal muscle and liver. The two primary sites of metabolic dysfunction in aging and metabolic syndrome. The peptide structure (hydrophilic, positively charged at physiological pH) allows rapid cellular uptake without requiring active transport.

NR requires daily dosing at 300–1000mg to maintain elevated NAD+ levels because the salvage pathway runs continuously. NAD+ is consumed constantly by sirtuins, PARPs, and CD38 enzymes. MOTS-c produces sustained AMPK activation with administration 2–3 times weekly in rodent longevity studies published in Cell Metabolism. The signaling cascade it triggers persists beyond the peptide's plasma clearance.

NAD+ Alternative to NR Supplements: Direct Comparison

Compound Mechanism Dosage & Frequency Bioavailability Primary Clinical Evidence Bottom Line
NR (Nicotinamide Riboside) Feeds NAD+ salvage pathway via NRK→NMNAT conversion 300–1000mg daily oral 15–25% reaches tissues intact (rest converts to NAM in gut/liver) Multiple human RCTs showing NAD+ elevation; mixed results on functional outcomes (exercise, cognition) Proven NAD+ booster but outcome data inconsistent. Works if salvage pathway is functional
MOTS-c Peptide Activates AMPK directly; increases mitochondrial biogenesis independent of NAD+ 5–15mg subcutaneous 2–3×/week ~90% subcutaneous bioavailability (bypasses gut metabolism) Phase 1 human trial showed improved insulin sensitivity; rodent data robust for longevity/exercise Targets energy dysfunction upstream of NAD+. Requires injection, limited human trial volume
NMN (Nicotinamide Mononucleotide) One step closer to NAD+ than NR (skips NRK step) 250–500mg daily oral Likely similar to NR (gut metabolism reduces intact absorption) Human trials emerging; rodent data shows faster NAD+ elevation vs NR Theoretical advantage over NR but human evidence still limited. Cost typically higher
MitoQ (Mitochondrial Antioxidant) Delivers CoQ10 directly to mitochondrial matrix via TPP+ cation 10–20mg daily oral Mitochondrial accumulation 100–800× higher than unmodified CoQ10 Human trials in heart failure, kidney disease show reduced oxidative stress; no longevity RCTs Reduces oxidative damage but doesn't increase energy production. Complementary, not equivalent

What If: NAD+ Alternative Scenarios

What If I've Been Taking NR for Months Without Noticeable Results?

Consider whether NAD+ depletion is actually your primary metabolic bottleneck. If NAMPT activity is low (common in chronic inflammation, metabolic syndrome, or advanced age), feeding the salvage pathway with more substrate won't produce proportional outcomes. Blood NAD+ measurement via metabolomics panels can confirm whether supplementation is raising levels. If NAD+ increases but symptoms don't improve, the dysfunction likely sits downstream (mitochondrial efficiency, oxidative stress, insulin resistance). MOTS-c targets those directly.

What If I Want to Combine MOTS-c with NAD+ Precursors?

The mechanisms are non-overlapping, making combination theoretically synergistic. NR provides substrate for NAD+-dependent enzymes (sirtuins, PARPs); MOTS-c activates AMPK to improve how mitochondria use that substrate. Rodent studies combining mitochondrial peptides with NAD+ boosters showed additive effects on endurance capacity and metabolic markers. Start one compound at a time to isolate response. Adding both simultaneously makes it impossible to determine which (if either) is driving observed changes.

What If I'm Concerned About Peptide Stability and Storage?

MOTS-c is a synthetic 16-amino-acid peptide. Far more stable than full-length proteins but still requires proper handling. Lyophilised (freeze-dried) powder stored at −20°C remains stable for 12+ months. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Any temperature excursion above 25°C for extended periods (8+ hours) risks peptide degradation. Our MOTS-C Nasal Spray formulation is pre-mixed and stable for 90 days refrigerated. Eliminating reconstitution variables entirely.

The Unflinching Truth About NAD+ Boosting

Here's the honest answer: oral NAD+ precursors work inconsistently because the salvage pathway isn't always the limiting step. Most NR studies measure NAD+ levels in blood. Which increased reliably across trials. But functional outcomes (strength, endurance, cognitive performance, glucose control) showed massive variability. A 2022 meta-analysis in Nutrients reviewed 17 human RCTs and found NAD+ elevation occurred in 94% of studies, but only 35% showed statistically significant improvement in at least one functional outcome measure.

The disconnect exists because raising NAD+ doesn't automatically improve mitochondrial function if the mitochondria themselves are damaged, inefficient, or insufficient in number. MOTS-c addresses that root cause. It signals cells to build more mitochondria and optimize the ones already present. It's not a substrate; it's a regulatory signal.

Peptide-based alternatives require more effort (reconstitution, injection technique, cold storage) compared to swallowing a pill. The trade-off is mechanism specificity. If your goal is cellular energy optimization and you're willing to engage with research-grade compounds, MOTS-c represents a fundamentally different approach than NAD+ precursor supplementation.

Why Mitochondrial Peptides Target Dysfunction Differently

Mitochondrial-derived peptides (MDPs) like MOTS-c are encoded by mitochondrial DNA and act as autocrine/paracrine signals. Mitochondria use them to communicate stress, damage, or functional capacity to the rest of the cell. This is a recently characterised signaling system; MOTS-c was first identified in 2015. Its primary function appears to be metabolic adaptation under stress. Exercise, fasting, cold exposure all increase MOTS-c expression.

When you administer exogenous MOTS-c, you're mimicking that endogenous stress-response signal without requiring the stressor itself. The cell interprets it as "energy demand is high; increase capacity." AMPK activation follows, triggering mitochondrial biogenesis via PGC-1α upregulation. New mitochondria are built. Existing mitochondria undergo fusion (combining damaged units into functional ones) and fission (removing irreparably damaged components via mitophagy).

NAD+ is required for many of these processes. Sirtuins and PARPs are NAD+-dependent. But it's a cofactor, not the signal initiating the cascade. Raising NAD+ without activating the pathways that use it is like adding gasoline to a car with a broken engine. MOTS-c starts the engine; NAD+ is the fuel. Both matter, but the signal comes first.

Research-grade peptides require precise amino-acid sequencing and purity verification to function as intended. Every peptide in our catalog undergoes third-party HPLC and mass spectrometry testing to confirm >98% purity and correct molecular weight. Contaminants, truncated sequences, or incorrect folding render peptides inactive or unpredictable. Real Peptides manufactures exclusively through small-batch synthesis with exact amino-acid sequencing, guaranteeing lab reliability across every vial.

NAD+ alternative to NR supplements isn't about replacing one molecule with another. It's about choosing the intervention that matches the actual dysfunction. If NAD+ is depleted and salvage enzymes function normally, NR works. If mitochondrial capacity is the bottleneck, peptides work. Most metabolic decline involves both, which is why combination approaches show the strongest outcomes in preliminary research. The field is early. MOTS-c has one completed Phase 1 human trial versus dozens for NR. But the mechanistic rationale is sound and the rodent longevity data is among the most compelling published to date.

References

Peer-reviewed sources on MOTS-c indexed in PubMed, listed for research context. Real Peptides supplies MOTS-c for laboratory research use only.

  1. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free radical biology & medicine, 2026. PMID 41520850. doi:10.1016/j.freeradbiomed.2026.01.002
  2. Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction. Biomedicines, 2026. PMID 42193373. doi:10.3390/biomedicines14051048
  3. MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation. Autophagy, 2026. PMID 42153537. doi:10.1080/15548627.2026.2677180
  4. Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis. Free radical biology & medicine, 2026. PMID 41933740. doi:10.1016/j.freeradbiomed.2026.03.074
  5. MOTS-c attenuates cardiac dysfunction following high altitude exposure by promoting mitophagy. Free radical biology & medicine, 2026. PMID 41654147. doi:10.1016/j.freeradbiomed.2026.01.064
  6. Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Experimental & molecular medicine, 2025. PMID 40855115. doi:10.1038/s12276-025-01521-1
  7. MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. Free radical biology & medicine, 2025. PMID 41043625. doi:10.1016/j.freeradbiomed.2025.09.056
  8. MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. American journal of respiratory cell and molecular biology, 2025. PMID 40035775. doi:10.1165/rcmb.2024-0533OC

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA that activates AMPK (AMP-activated protein kinase) directly, bypassing the NAD+ salvage pathway entirely. Unlike NR, which increases NAD+ by feeding the salvage cycle through NAMPT-dependent conversion, MOTS-c signals mitochondria to improve oxidative efficiency, increase biogenesis, and enhance glucose uptake without requiring NAD+ elevation. It's a regulatory signal, not a metabolic substrate — functionally complementary to NAD+ precursors but mechanistically independent.
No — MOTS-c does not directly increase NAD+ levels. It activates AMPK, which triggers downstream pathways including mitochondrial biogenesis and improved oxidative phosphorylation. Some of those pathways (sirtuin activity, PARP function) require NAD+ as a cofactor, so optimal outcomes may involve adequate NAD+ availability, but MOTS-c itself doesn't boost NAD+ synthesis. It targets energy dysfunction upstream of NAD+ dependency, making it a complementary rather than equivalent intervention.
Research-grade MOTS-c typically costs $80–$150 per 5mg vial, with dosing protocols using 5–15mg administered 2–3 times weekly — approximately $240–$900 monthly depending on dose and frequency. NR supplements at therapeutic doses (500–1000mg daily) cost $40–$80 monthly. MOTS-c is significantly more expensive per month but requires less frequent administration and bypasses oral bioavailability losses that affect NR. The cost trade-off is mechanism specificity versus convenience.
Published human trials report minimal adverse events — the Phase 1 study in healthy adults found mild transient injection site redness in <10% of participants with no systemic side effects at doses up to 15mg. Rodent studies at 10× human-equivalent doses showed no toxicity markers. Because MOTS-c is an endogenous peptide (naturally produced by mitochondrial DNA), the body recognises it as a native signaling molecule. Long-term human safety data remains limited — the longest published human trial was 12 weeks.
NMN (nicotinamide mononucleotide) sits one enzymatic step closer to NAD+ than NR, theoretically requiring less conversion. Rodent studies show faster NAD+ elevation with NMN versus NR, but human bioavailability data is mixed — both undergo significant gut and liver first-pass metabolism that reduces intact tissue delivery. The few head-to-head human trials published show no significant functional outcome differences between NMN and NR at equivalent NAD+-raising doses. NMN typically costs 1.5–2× more than NR without clear human evidence of superiority.
Yes — the mechanisms are non-overlapping and theoretically synergistic. NR increases NAD+ availability as a substrate for energy-dependent enzymes; MOTS-c activates AMPK to improve how mitochondria use that substrate. Rodent studies combining mitochondrial peptides with NAD+ boosters showed additive effects on endurance and metabolic markers without adverse interactions. Start one compound at baseline and add the second after 4–6 weeks to isolate individual response. No human trials have formally tested the combination.
AMPK phosphorylation (the immediate molecular response) occurs within 30–60 minutes of administration in cell culture models. Functional outcomes in human trials — improved insulin sensitivity, exercise capacity — appeared at 4–8 weeks with consistent dosing. Mitochondrial biogenesis (creation of new mitochondria) requires weeks to months because it involves gene transcription, protein synthesis, and organelle assembly. Subjective energy improvements are typically reported within 2–3 weeks in anecdotal user reports, though placebo-controlled human data on subjective outcomes remains limited.
Oral NAD+ itself is not bioavailable — it's broken down in the gut before reaching systemic circulation, which is why precursors like NR and NMN are used instead. Injectable peptides like MOTS-c bypass gut metabolism entirely, achieving significantly higher bioavailability (~90% subcutaneous versus 15–25% oral for NR). The functional difference: oral precursors feed existing pathways with more substrate; injectable peptides activate signaling cascades directly. Injections require more user effort (reconstitution, sterile technique, cold storage) but deliver compounds that cannot survive oral administration.
MOTS-c improved insulin sensitivity and glucose tolerance in human trials published in *Nature Medicine*, with rodent studies showing reduced fat mass and improved metabolic markers comparable to caloric restriction. The mechanism involves AMPK activation, which increases glucose uptake, enhances fatty acid oxidation, and improves mitochondrial efficiency — all metabolically favourable. It is not a weight-loss drug in the traditional sense (no appetite suppression, no direct lipolysis), but by improving how cells process and use energy, it supports metabolic health outcomes that often include fat loss when combined with dietary structure.
Because NAD+ is a cofactor, not a signal — raising it doesn't automatically improve function if the pathways using it are damaged or inactive. A 2022 meta-analysis found 94% of NR trials increased blood NAD+ levels, but only 35% showed statistically significant functional improvements. The disconnect occurs when mitochondrial capacity, oxidative stress, or insulin resistance are the primary bottlenecks — adding more NAD+ substrate to a dysfunctional system doesn't fix the dysfunction itself. MOTS-c targets those root causes directly by activating repair and biogenesis pathways, which is why peptide-based approaches represent a mechanistically different intervention.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now